Breaking Finance News

Intercept Pharmaceuticals (NDAQ:ICPT) target price raised to $244.00, issued a report today by RBC Capital Markets

Intercept Pharmaceuticals (NDAQ:ICPT) had its target price raised to $244.00 by RBC Capital Markets in a report released 9/15/2017. The new target price indicates a possible upside of 1.58% based on the company's last closing price.

Yesterday Intercept Pharmaceuticals (NDAQ:ICPT) traded 6.62% higher at $94.54. The company’s 50-day moving average is $109.46 and its 200-day moving average is $116.57. The last closing price is down -20.05% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 1,138,832 shares of the stock were exchanged, up from an average trading volume of 572,128

See Chart Below

Intercept Pharmaceuticals (NDAQ:ICPT)

Intercept Pharmaceuticals has a 52 week low of $85.88 and a 52 week high of $172.95 The company’s market cap is currently $0.

In addition to RBC Capital Markets reporting its target price, a total of 17 firms have reported on the stock. The consensus target price is $222.82 with 5 firms rating the stock a strong buy, 8 firms rating the stock a buy, 3 firms rating the stock a hold, 2 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Intercept Pharmaceuticals (NDAQ:ICPT)

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.